GSK vs. PFE
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Pfizer Inc. (PFE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or PFE.
Correlation
The correlation between GSK and PFE is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GSK vs. PFE - Performance Comparison
Key characteristics
GSK:
-0.21
PFE:
-0.31
GSK:
-0.12
PFE:
-0.28
GSK:
0.99
PFE:
0.97
GSK:
-0.19
PFE:
-0.13
GSK:
-0.34
PFE:
-0.60
GSK:
16.11%
PFE:
12.48%
GSK:
26.51%
PFE:
24.27%
GSK:
-55.21%
PFE:
-58.96%
GSK:
-15.61%
PFE:
-56.43%
Fundamentals
GSK:
$75.93B
PFE:
$129.20B
GSK:
$1.65
PFE:
$1.41
GSK:
22.73
PFE:
16.16
GSK:
0.36
PFE:
0.54
GSK:
2.42
PFE:
2.03
GSK:
4.19
PFE:
1.44
GSK:
$24.01B
PFE:
$48.75B
GSK:
$16.98B
PFE:
$31.22B
GSK:
$5.14B
PFE:
$12.18B
Returns By Period
In the year-to-date period, GSK achieves a 11.89% return, which is significantly higher than PFE's -12.18% return. Over the past 10 years, GSK has outperformed PFE with an annualized return of 2.53%, while PFE has yielded a comparatively lower 0.48% annualized return.
GSK
11.89%
-2.30%
2.01%
-4.78%
1.57%
2.53%
PFE
-12.18%
-9.08%
-16.83%
-3.58%
-4.21%
0.48%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK vs. PFE — Risk-Adjusted Performance Rank
GSK
PFE
GSK vs. PFE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GSK vs. PFE - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 4.15%, less than PFE's 7.37% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.15% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
PFE Pfizer Inc. | 7.37% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.54% | 3.70% | 3.48% | 3.34% |
Drawdowns
GSK vs. PFE - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.21%, smaller than the maximum PFE drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for GSK and PFE. For additional features, visit the drawdowns tool.
Volatility
GSK vs. PFE - Volatility Comparison
GlaxoSmithKline plc (GSK) has a higher volatility of 11.15% compared to Pfizer Inc. (PFE) at 10.22%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
GSK vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities